Navigation Links
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
Date:12/10/2007

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL), today reported phase 1 data from an ongoing phase 1 trial of XL019 in patients with myelofibrosis, a myeloproliferative disorder (MPD). XL019 is an investigational small molecule that selectively inhibits the tyrosine kinase JAK2, one of four JAK family members activated in response to cytokines and hematopoietic growth factors. JAK2 is inappropriately activated in the majority of MPD patients and is deregulated in a number of solid tumors, including certain subtypes of lymphoma. Dr. Srdan Verstovsek from the M. D. Anderson Cancer Center, Houston, TX today presented data from an ongoing phase 1 study in an oral presentation session (Abstract #553) at the American Society of Hematology 49th Annual Meeting and Exposition, which is taking place in Atlanta, December 8th-11th.

"We are very encouraged by the results from this ongoing trial that show rapid decrease in spleen size and relief of disease-related symptoms at low doses of XL019. XL019 is a highly selective inhibitor of JAK2 that may have the potential to provide important benefit for patients with myeloproliferative disorders and other diseases driven by JAK2," said Michael Morrissey, Ph.D., president of research and development at Exelixis. "We believe that JAK2 is a critical target in myeloproliferative disorders, and effective inhibition of JAK2 may directly translate into clinical benefit. The strong linkage of JAK2 to MPDs provides a potentially quick route to market, with potential for additional opportunities in larger commercial indications. We are planning to initiate pivotal trials of XL019 in myelofibrosis patients in 2008."

Trial Design

The phase 1 dose escalation study of XL019 is ongoing in subjects with primary myelofibrosis (MF) and post-polycythemia vera/essential thrombocythemia MF. To date nine patients have been enrolled. The primary objective of this study is to determine the safety and tol
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... -- Champions Oncology (OTC: CSBR), a company engaged in the ... the development and use of oncology drugs, today announced ... the fourth quarter and fiscal year ended April 30, ... The company will host a conference call ... EDT (1:30 p.m. PDT). To participate in the call, ...
(Date:7/21/2014)... YORK , July 21, 2014  EHE International, ... exams with a nationwide physician network, today announced that ... Las Vegas, NV has been named an ... the Las Vegas region now ... help proactively maintain their health. "EHE ...
(Date:7/21/2014)... 2014 A ... biosimilars/follow-on-biologics market (types, applications and geography) - Size, ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... reach $35 billion by 2020 from the estimated ... regulatory pathways in developed markets and higher efficacy ...
Breaking Medicine Technology:EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 3Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 4
... ANA598 demonstrates favorable preclinical antiviral, metabolic, ... preliminary toxicologic properties, SAN DIEGO, Sept. 11 ... preclinical data today on ANA598, a,non-nucleoside inhibitor of ... the 14th International Symposium on Hepatitis C Virus ...
... have or have,ever had chronic heartburn, you may be ... severe gastroesophageal reflux disease,(GERD). Barrett,s esophagus has been recognized ... esophagus, the seventh deadliest cancer in men in,the United ... in the lining of the,esophagus, which can progress to ...
Cached Medicine Technology:Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer 2
(Date:7/22/2014)... 22, 2014 Dr. Allen Kamrava, colorectal ... launch of a new website dedicated to the diagnosis ... be found at DrKamrava.com . , “With this ... a knowledgeable and trustworthy source for various colorectal ... hemorrhoids, fissures, gallstones, colon cancer, hernias, or more, patients ...
(Date:7/22/2014)... Angeles, CA (PRWEB) July 22, 2014 ... online marketing training course that takes a comprehensive, step-by-step ... scale an online marketing venture has just been released ... Hendricks. , “In the internet marketing world if you’re ... Hendricks. “And a lot of people simply give up ...
(Date:7/22/2014)... 2014 Eating certain foods can not only ... according to two of the world’s top cosmetic dentists. ... of the Anacapa Dental Art Institute in Oxnard and Woodland ... of one’s teeth. They are specially trained to replace missing ... not seeing a dentist regularly, and about two-thirds of the ...
(Date:7/22/2014)... Kirby Lester, LLC, the leading pharmacy automation ... functionality to perform a trackable double-count for any prescription ... double-count of controlled medications is required, the KL1Plus allows ... a second count of any tablet or capsule order. ... second count up to 10 years. This function is ...
(Date:7/22/2014)... 22, 2014 Industry-leading health business information ... release of Specialty Pharmacy Trends and Strategies: 2014 ... provides a comprehensive overview of the current state of ... strategies and tactics for:, , Specialty ... utilization concerns — including details of coinsurance levels by ...
Breaking Medicine News(10 mins):Health News:Los Angeles Doctor Launches Brand New Website for Colorectal Surgery and Treatment 2Health News:Los Angeles Doctor Launches Brand New Website for Colorectal Surgery and Treatment 3Health News:Info Cash 2.0: Review Of Chris Carpenter’s Online Marketing Training Released 2Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 2Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 3Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 4Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 5Health News:Kirby Lester KL1Plus Pharmacy Automation Perfect for Double-Counting & Tracking Prescriptions from Any Pharmacy Robot 2Health News:Latest Edition of Annual Book Provides Comprehensive Overview of the Specialty Pharmacy Arena 2
... radiation dose was equivalent to 113 chest X-rays, study finds ... of patients who have abdominal/pelvic CT scans receive additional unnecessary ... say. , In the study, 978 CT abdominal and pelvic ... 91 years. Most of the patients were 30 to 50 ...
... , LOS ANGELES, Nov. 30 Menopause ... brings with it a host of uncomfortable symptoms that negatively impact ... gain , night sweats and lethargy are just some of the ... and symptoms can show up a full ten years before ...
... , CARDIFF, Calif., Nov. 30 Jedi Mind, ... Company,s first thought-controlled game is complete and available for purchase. The ... user to play the game with the power of their mind ... be sold online at a price of $49 and can be ...
... CHARLTON, Mass., Nov. 30 Harrington Physician Services (HPS) is ... Devine, Leah Doret, Elizabeth Fuller and Monika Mathur to its ... Charlton-based physicians, coming from the Fallon Clinic, will soon join ... medical office building under construction at 10 North Main Street, ...
... , MINNEAPOLIS, Nov. 30 The Eject Helmet Removal System ... Top Fuel, Funny Car, Pro Stock Car and Pro Stock Motorcycle classes ... as well as for Top Alcohol dragster and Top Alcohol Funny Car ... is the only product that allows medical caregivers at race tracks and ...
... discussion in the scientific community, the Institute for Quality ... for evaluating the relation between cost and benefit. The ... certain commissions awarded by the Federal Joint Committee (G-BA). ... on recommendations to the GKV-Spitzenverband [National Association of Health ...
Cached Medicine News:Health News:CT Scan Patients May Get Unnecessary Imaging 2Health News:Anti-Aging Institute of California Offers New Natural Solution for Menopause Symptoms 2Health News:First Thought-Controlled Game Complete From Jedi Mind, Inc. 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 3Health News:National Hot Rod Association Mandates Eject Helmet Removal System for 2010 2Health News:IQWiG presents a method for evaluating the relation between cost and benefit 2Health News:IQWiG presents a method for evaluating the relation between cost and benefit 3Health News:IQWiG presents a method for evaluating the relation between cost and benefit 4Health News:IQWiG presents a method for evaluating the relation between cost and benefit 5
... come back with better resolution, accuracy and ... 25 or 31 rings (same as TMS-1), ... provides high accuracy & repeatability. The small ... & provides extensive corneal coverage. The low ...
... Pachycam is the first compact and ... The OCULUS Pachycam has automatic ... pressure) in accordance with Shah or ... The OCULUS Pachycam is non-contact ...
World's first commercially available vacuum assisted biopsy device for MRI....
... stereotactic, ultrasound and MRI-guided vacuum assisted breast ... Use the patented, FDA-cleared ATEC system for ... advanced method of breast biopsy. Its compassionate ... who trust YOU.,12 Gauge Handpieces: Useful for ...
Medicine Products: